Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has had discussions with the Department of Health in Northern Ireland on the use of (a) Lecanemab and (b) Donanemab in the treatment of dementia.

The Department is working closely together with system partners to plan for the implementation of new dementia medicines such as lecanemab and donanemab, should they be granted a marketing authorisation in the United Kingdom and a positive National Institute for Health and Care Excellence (NICE) recommendation. Partners include the Medicines and Healthcare products Regulatory Agency, NICE, NHS England, the Office for Life Sciences, and the devolved administrations, including the Department of Health in Northern Ireland.